119 related articles for article (PubMed ID: 1797198)
1. Oral administration of [3H]navelbine in patients: comparative pharmacokinetics using radioactive and radioimmunologic determination methods.
Rahmani R; Zhou XJ; Boré P; Van Cantfort J; Focan C; Cano JP
Anticancer Drugs; 1991 Aug; 2(4):405-10. PubMed ID: 1797198
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of a new anticancer drug, navelbine, in patients. Comparative study of radioimmunologic and radioactive determination methods.
Boré P; Rahmani R; van Cantfort J; Focan C; Cano JP
Cancer Chemother Pharmacol; 1989; 23(4):247-51. PubMed ID: 2924381
[TBL] [Abstract][Full Text] [Related]
3. Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography.
van Tellingen O; Kuijpers AV; Beijnen JH; Nooijen WJ; Bult A
Invest New Drugs; 1993; 11(2-3):141-50. PubMed ID: 8262726
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of navelbine after oral administration in cancer patients.
Zhou XJ; Boré P; Monjanel S; Sahnoun Z; Favre R; Durand A; Rahmani R
Cancer Chemother Pharmacol; 1991; 29(1):66-70. PubMed ID: 1742851
[TBL] [Abstract][Full Text] [Related]
5. The clinical pharmacokinetics of vinorelbine (Navelbine).
Wargin WA; Lucas VS
Semin Oncol; 1994 Oct; 21(5 Suppl 10):21-7. PubMed ID: 7973765
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of navelbine after oral administration in the dog and the monkey.
Zhou XJ; Landi H; Breillout F; Rahmani R
Anticancer Drugs; 1993 Aug; 4(4):511-5. PubMed ID: 8400355
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography.
Jehl F; Quoix E; Leveque D; Pauli G; Breillout F; Krikorian A; Monteil H
Cancer Res; 1991 Apr; 51(8):2073-6. PubMed ID: 1849042
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
[TBL] [Abstract][Full Text] [Related]
9. Biliary elimination and pharmacokinetics of vinorelbine in micropigs.
Levêque D; Merle-Melet M; Bresler L; Didelot JP; Aymard JP; Wihlm J; Jehl F
Cancer Chemother Pharmacol; 1993; 32(6):487-90. PubMed ID: 8258199
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic profile of vinorelbine, a new semi-synthetic vinca alkaloid, determined by high-performance liquid chromatography.
Levêque D; Jehl F; Quoix E; Monteil H
Xenobiotica; 1993 Nov; 23(11):1325-33. PubMed ID: 8310715
[TBL] [Abstract][Full Text] [Related]
11. [Clinical pharmacokinetics of navelbine after oral administration, in vitro metabolism and interindividual variability].
Sahnoun Z; Zhou XJ; Bore P; Monjanel S; Favre R; Durand A; Rahmani R
Bull Cancer; 1990; 77(11):1115-21. PubMed ID: 2275987
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer.
Levêque D; Quoix E; Dumont P; Massard G; Hentz JG; Charloux A; Jehl F
Cancer Chemother Pharmacol; 1993; 33(2):176-8. PubMed ID: 8261579
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of antitumor activity of navelbine (vinorelbine ditartrate) against human breast carcinoma xenografts based on its pharmacokinetics in nude mice.
Tsuruo T; Inaba M; Tashiro T; Yamori T; Ohnishi Y; Ashizawa T; Sakai T; Kobayashi S; Gomi K
Anticancer Drugs; 1994 Dec; 5(6):634-40. PubMed ID: 7888700
[TBL] [Abstract][Full Text] [Related]
14. Relative bioavailability of two oral formulations of navelbine in cancer patients.
Zhou XJ; Zhou-Pan XR; Favre R; Rahmani R
Biopharm Drug Dispos; 1994 Oct; 15(7):577-86. PubMed ID: 7849233
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of vinorelbine.
Levêque D; Jehl F
Clin Pharmacokinet; 1996 Sep; 31(3):184-97. PubMed ID: 8877249
[TBL] [Abstract][Full Text] [Related]
16. Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer.
Gauvin A; Pinguet F; Culine S; Astre C; Cupissol D; Bressolle F
Cancer Chemother Pharmacol; 2002 Jan; 49(1):48-56. PubMed ID: 11855752
[TBL] [Abstract][Full Text] [Related]
17. The effects of food and divided dosing on the bioavailability of oral vinorelbine.
Rowinsky EK; Lucas VS; Hsieh AL; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Donehower RC
Cancer Chemother Pharmacol; 1996; 39(1-2):9-16. PubMed ID: 8995494
[TBL] [Abstract][Full Text] [Related]
18. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group.
Johansen M; Kuttesch J; Bleyer WA; Krailo M; Ames M; Madden T
Clin Cancer Res; 2006 Jan; 12(2):516-22. PubMed ID: 16428494
[TBL] [Abstract][Full Text] [Related]
19. Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer.
Winer EP; Chu L; Spicer DV
Semin Oncol; 1995 Apr; 22(2 Suppl 5):72-8; discussion 78-9. PubMed ID: 7740337
[TBL] [Abstract][Full Text] [Related]
20. The absolute bioavailability of oral vinorelbine in patients with solid tumors.
Lush RM; McCune JS; Tetteh L; Thompson JA; Mahany JJ; Garland L; Suttle AB; Sullivan DM
Cancer Chemother Pharmacol; 2005 Dec; 56(6):578-84. PubMed ID: 16001165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
